Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time

Knowing the survival rate for bladder cancer is key for patients and their families. The survival rate shows how many people live with a certain cancer for a set time after being diagnosed.

Recent SEER data show the 5-year relative bladder cancer survival rate in the US is about 79%. This means 79% of people with the same type and stage of bladder cancer are alive 5 years after diagnosis. This is compared to the general population.

Bladder Cancer Survival Rate: Crucial Current Statistics
Bladder Cancer Survival Rate: Crucial Current Statistics 4

The bladder cancer prognosis changes a lot based on when it’s found. Finding cancer early and getting care from many doctors helps. This improves survival rates and life quality for many every year.

Key Takeaways

  • The overall 5-year relative survival rate for bladder cancer in the US is around 79%.
  • Survival rates depend significantly on the stage at diagnosis.
  • Early detection and multidisciplinary care are improving survival rates.
  • Bladder cancer prognosis varies based on the stage and type of cancer.
  • Understanding survival statistics is key for patients and their families.

Understanding Bladder Cancer Survival Rate

Bladder cancer survival rates are key to understanding the disease’s impact and treatment success. Our institution leads in diagnosis, surgery, and treatments like immunotherapy. We aim to be among the best globally in treating bladder cancer.

Definition and Measurement Methods

The 5-year relative survival rate is a common way to predict bladder cancer outcomes. It compares patients with the same cancer type and stage to the general population. Survival rates are based on past results of many people with the same cancer.

Survival rates are usually measured over 5 years. This gives a clear view of the disease’s prognosis. It helps doctors and patients understand the chances of survival after diagnosis.

Bladder Cancer Survival Rate: Crucial Current Statistics
Bladder Cancer Survival Rate: Crucial Current Statistics 5

Factors Affecting Survival Statistics

Many things can change bladder cancer survival rates. The cancer’s stage, type, and the patient’s health are key. The stage at diagnosis is very important because it affects treatment choices and results.

Other factors that play a role include:

  • The type of bladder cancer, such as urothelial carcinoma or other rare types
  • The patient’s age and overall health status
  • The presence of comorbidities or other health conditions
  • The effectiveness of the treatment plan and the patient’s response to it

Knowing these factors helps doctors create tailored treatment plans. It also helps patients make better choices about their care.

Overall Bladder Cancer Survival Statistics

It’s key for patients and doctors to know bladder cancer survival stats. These numbers show how well treatments work and why catching cancer early is so important.

Current 5-Year Survival Rate in the United States

Recent SEER data show the 5-year survival rate for bladder cancer in the U.S. is about 79%. This means 79% of people with bladder cancer are alive 5 years after being diagnosed.

The 5-year survival rate is a key measure for bladder cancer patients. It shows how well someone might do based on how far the cancer has spread. The SEER database tracks these rates for different cancer stages, giving a full picture of survival chances.

Key Statistics:

  • Overall 5-year relative survival rate: around 79%
  • The EER database tracks survival rates based on cancer spread
  • Survival rates vary significantly by cancer stage at diagnosis

Bladder Cancer Mortality Rate Trends

Looking at bladder cancer death rate trends helps us see how treatments are doing. Studies show death rates for bladder cancer are going down in many places, including the U.S.

This drop is thanks to better treatments like new surgeries and immunotherapy. Also, catching cancer early is key to better survival rates.

Bladder Cancer Survival Rate: Crucial Current Statistics
Bladder Cancer Survival Rate: Crucial Current Statistics 6
  1. Declining mortality rates in the United States and other countries
  2. Advancements in surgical techniques and immunotherapy
  3. Increased focus on early detection and diagnosis

By studying these trends and stats, we can understand where bladder cancer treatment stands today. We can also find ways to make it even better.

Survival Rates by Cancer Stage

Bladder cancer survival rates depend a lot on when it’s found. Knowing how survival changes with each stage helps both patients and doctors make better choices.

In Situ Bladder Cancer

Carcinoma in situ, or stage 0 bladder cancer, has a very high survival rate. Patients with this type of cancer have a 97.9% 5-year survival rate. This is because the cancer is only in the bladder lining and hasn’t spread.

Localized Bladder Cancer

For localized bladder cancer, where the cancer is in the bladder but has grown into the muscle, the 5-year survival rate is 72.6%. This stage is important for treatment because the cancer is mostly contained but needs strong action.

The 5-year survival rates for bladder cancer vary a lot by stage. The rates are:

  • 97% for carcinoma in situ
  • 71% for localized bladder cancer
  • 39% for regional bladder cancer
  • 8% for metastatic bladder cancer

These numbers show how key early detection and quick treatment are. Patients found early have a much better chance of living longer. As we keep improving treatments, knowing these survival rates helps us focus on what each patient needs.

How Age and Other Factors Impact Bladder Cancer Prognosis

Bladder cancer’s outcome depends on age, gender, and health. Knowing these factors helps both patients and doctors make better treatment choices.

Bladder Cancer Survival Rates by Age

Age greatly affects bladder cancer survival rates. Older patients usually have lower survival rates than younger ones. Studies show that those under 60 have a better chance of survival than those over 75. The 5-year survival rate for bladder cancer patients under 60 is significantly higher than for those in older age groups.

“The age of the patient at diagnosis is an important prognostic factor for bladder cancer,” says a leading urologist. “Younger patients typically have fewer comorbidities and can tolerate more aggressive treatments, which can improve their survival rates.”

Impact of Gender, Race, and Comorbidities

Gender, race, and health conditions also affect bladder cancer prognosis. Men are more likely to get bladder cancer, but often have better survival rates. Women, on the other hand, tend to have more advanced disease, which can lower their survival rates. Certain racial groups have different survival rates due to genetic and environmental factors.

  • Men have a higher incidence of bladder cancer but often better survival rates than women.
  • African American patients may have different survival rates compared to Caucasian patients due to genetic factors.
  • Patients with comorbidities such as diabetes or heart disease may have a poorer prognosis.

Advances in diagnosis, surgery, and treatments are improving bladder cancer outcomes. Understanding how age and other factors influence prognosis helps tailor treatments. This can lead to better survival rates for patients.

Treatment Advances Improving Bladder Cancer Cure Rate

New surgical methods, immunotherapy, and team care have changed how we treat bladder cancer. These changes are making it easier to cure the disease and helping patients do better overall.

Surgical Innovations and Success Rates

Surgery for bladder cancer has gotten much better. Now, we have:

  • Less invasive surgeries that heal faster
  • Robotic surgeries that are more precise
  • Better imaging to see tumors clearly

These improvements mean more people are getting better and living longer.

Immunotherapy Breakthroughs

Immunotherapy is a new and exciting way to fight bladder cancer. The big news includes:

  1. Checkpoint inhibitors that work really well
  2. Personalized treatments based on each patient’s cancer
  3. Combining treatments to get even better results

These advances are giving patients new hope and better chances of beating the disease.

Multidisciplinary Approaches at Leading Centers

Top hospitals like Liv Hospital are leading the way with team care. They bring together experts from different areas to give patients the best care. This teamwork is key to helping more people survive bladder cancer.

By using the latest treatments and strategies, we can tailor care to each patient. This not only helps them get better but also improves their quality.

Conclusion: Living with Bladder Cancer

Knowing about bladder cancer survival rates is key for patients. It helps them make smart choices about their health. We’ve looked at the survival stats and what affects them.

Survival numbers give us clues, but they don’t tell the whole story. It’s important for patients to talk to their doctors. This way, they can understand their own situation better.

We aim to improve care and focus on the patient at our institution. By choosing top centers and staying updated, patients can boost their survival chances. This also improves their quality.

FAQ

What is the overall 5-year survival rate for bladder cancer in the United States?

The 5-year survival rate for bladder cancer in the U.S. changes based on when it’s found. We have the latest stats on this.

How does the stage of bladder cancer at diagnosis affect survival rates?

The stage at diagnosis greatly affects survival chances. Rates range from 97.9% for early stages to 72.6% for more advanced ones.

What are the survival rates for different types of bladder cancer?

Survival rates depend on the type and stage of bladder cancer. Knowing these details is key to understanding the prognosis.

How does age impact bladder cancer prognosis and survival rates?

Age is a big factor in bladder cancer survival. Rates vary by age, and this info helps tailor treatments.

What role do gender, race, and comorbidities play in bladder cancer survival rates?

Gender, race, and health conditions also affect survival. These, along with age, shape the prognosis and treatment plans.

What advances in treatment have improved the cure rate for bladder cancer?

New surgical methods, immunotherapy, and team-based care have boosted cure rates. Leading centers lead these advancements.

What is the cancer-specific survival rate by stage of bladder cancer?

Survival rates by stage show how well treatments work for different bladder cancer stages.

How have bladder cancer mortality rate trends changed over time?

Tracking mortality trends helps us see how well treatments are working. It also highlights the need for early detection.

What is the significance of early detection in improving bladder cancer survival rates?

Finding bladder cancer early is vital for better survival chances. Early diagnosis greatly improves treatment success.


References

  1. American Cancer Society. (2025). Bladder cancer survival rates.https://www.cancer.org/cancer/bladder-cancer/detection-diagnosis-staging/survival-rates.html
  2. National Cancer Institute. (2025). SEER cancer stat facts: Bladder cancer.https://seer.cancer.gov/statfacts/html/urinb.html
  3. National Institute for Health and Care Excellence (NICE). (2023). Bladder cancer: diagnosis and management.https://www.nice.org.uk/guidance/ng234
i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Get a Free Quote

Response within 2 hours during business hours

Clinics/branches
GDPR

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
Trusted Worldwide
30
Years of
Experience
30 Years Badge
Health Türkiye Accreditation

Trusted Worldwide

30 Years of Experience

Patient Reviews
Reviews from 9,651
4,9
Was this content helpful?
Your feedback helps us improve.
What did you like?
Share more details about your experience.
You must give consent to continue.

Thank you!

Your feedback has been submitted successfully. Your input is valuable in helping us improve.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 510 67 91